NextCure, a clinical-stage biotech developing next-gen cancer immunotherapies, raised $75 million by offering 5 million shares at $15, the midpoint of the range of $14 to $16.
NextCure plans to list on the Nasdaq under the symbol NXTC. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray acted as lead managers on the deal.
Cancer biotech NextCure prices IPO at $15 midpoint
May 8, 2019

